Qiming U.S. Healthcare Fund II, L.P. 4
4 · Elevation Oncology, Inc. · Filed Jul 1, 2021
Insider Transaction Report
Form 4
Qiming U.S. Healthcare Fund II, L.P.
10% Owner
Transactions
- Conversion
Series A Preferred Stock
2021-06-29−7,000,000→ 0 total→ Common Stock (1,656,577 underlying) - Conversion
Common Stock
2021-06-29+401,065→ 2,057,642 total - Purchase
Common Stock
2021-06-29$16.00/sh+312,500$5,000,000→ 2,370,142 total - Conversion
Series B Preferred Stock
2021-06-29−1,694,730→ 0 total→ Common Stock (401,065 underlying) - Conversion
Common Stock
2021-06-29+1,656,577→ 1,656,577 total
Footnotes (2)
- [F1]The Shares of the Issuer's Preferred Stock automatically converted on a 4.225582-for-one basis into the number of shares of the Issuer's Common Stock in shown in column 7 immediately upon the closing of the Issuer's initial public offering, and had no expiration date.
- [F2]The securities are directly held by Qiming U.S. Healthcare Fund II, L.P. ("Qiming"). Qiming U.S. Healthcare GP II, LLC ("Qiming GP") is the General Partner of Qiming, and may deem beneficial ownership of shares held by Qiming, and includes Gary Rieschel, as Managing Member of Qiming GP, and Mark McDade, Co-Founder, and Partner of Qiming, that each may share voting and investment power of the shares held by Qiming.